RU2326119C2 - 2-циано-4-аминопиримидиновые соединения с ингибирующим действием на катепсин к, фармацевтическая композиция и способы их получения (варианты) - Google Patents
2-циано-4-аминопиримидиновые соединения с ингибирующим действием на катепсин к, фармацевтическая композиция и способы их получения (варианты) Download PDFInfo
- Publication number
- RU2326119C2 RU2326119C2 RU2004109812/04A RU2004109812A RU2326119C2 RU 2326119 C2 RU2326119 C2 RU 2326119C2 RU 2004109812/04 A RU2004109812/04 A RU 2004109812/04A RU 2004109812 A RU2004109812 A RU 2004109812A RU 2326119 C2 RU2326119 C2 RU 2326119C2
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- piperazin
- methylpiperazin
- ethyl
- methoxyphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims description 18
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 102000005600 Cathepsins Human genes 0.000 title description 3
- 108010084457 Cathepsins Proteins 0.000 title description 3
- MRINWLDDTZFLSW-UHFFFAOYSA-N 4-aminopyrimidine-2-carbonitrile Chemical class NC1=CC=NC(C#N)=N1 MRINWLDDTZFLSW-UHFFFAOYSA-N 0.000 title 1
- -1 4-(1-propylpiperidine-4-yl)phenyl Chemical group 0.000 claims abstract description 232
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 20
- 102000004171 Cathepsin K Human genes 0.000 claims abstract description 18
- 108090000625 Cathepsin K Proteins 0.000 claims abstract description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims abstract description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 6
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims abstract description 4
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 229940123003 Cathepsin inhibitor Drugs 0.000 claims 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 125000000217 alkyl group Chemical group 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
- 125000004898 2,2-dimethylpropylamino group Chemical group CC(CN*)(C)C 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- SSLHMOMWYFQRLH-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)-n-(2,2-dimethylpropyl)pyrimidin-4-amine Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1CCl SSLHMOMWYFQRLH-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 0 CC(NCc1cnc(C#N)nc1N*)=O Chemical compound CC(NCc1cnc(C#N)nc1N*)=O 0.000 description 4
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 102000049698 human CTSK Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- VLOODHWTRPYFIS-UHFFFAOYSA-N 2,4-dichloro-5-(chloromethyl)pyrimidine Chemical compound ClCC1=CN=C(Cl)N=C1Cl VLOODHWTRPYFIS-UHFFFAOYSA-N 0.000 description 3
- MXYMOGCKIBDDPZ-UHFFFAOYSA-N 2-chloro-4-(2,2-dimethylpropylamino)pyrimidine-5-carbaldehyde Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1C=O MXYMOGCKIBDDPZ-UHFFFAOYSA-N 0.000 description 3
- ZREIEPRXRIDGIB-UHFFFAOYSA-N 5-(aminomethyl)-2-chloro-n-(2,2-dimethylpropyl)pyrimidin-4-amine Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1CN ZREIEPRXRIDGIB-UHFFFAOYSA-N 0.000 description 3
- VIAPXZXEMGTDPR-UHFFFAOYSA-N 5-(azidomethyl)-2-chloro-n-(2,2-dimethylpropyl)pyrimidin-4-amine Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1CN=[N+]=[N-] VIAPXZXEMGTDPR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003302 alkenyloxy group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- DIARHFIFVCJXDK-UHFFFAOYSA-N n-[[2-chloro-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CN=C(Cl)N=C1NCC(C)(C)C DIARHFIFVCJXDK-UHFFFAOYSA-N 0.000 description 3
- WPLXGOWCOPIUIS-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CN=C(C#N)N=C1NCC(C)(C)C WPLXGOWCOPIUIS-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 2
- BGPMUYLZRRZAKH-UHFFFAOYSA-N 2-chloro-4-(2,2-dimethylpropylamino)-n-[(4-methoxyphenyl)methyl]pyrimidine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CN=C(Cl)N=C1NCC(C)(C)C BGPMUYLZRRZAKH-UHFFFAOYSA-N 0.000 description 2
- BVQMBHQLHOFFID-UHFFFAOYSA-N 2-chloro-4-(2,2-dimethylpropylamino)pyrimidine-5-carboxylic acid Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1C(O)=O BVQMBHQLHOFFID-UHFFFAOYSA-N 0.000 description 2
- DPYRABWEGRCJDZ-UHFFFAOYSA-N 2-cyano-4-(2,2-dimethylpropylamino)pyrimidine-5-carboxylic acid Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1C(O)=O DPYRABWEGRCJDZ-UHFFFAOYSA-N 0.000 description 2
- ZYLZQIMSYNAILC-UHFFFAOYSA-N 2-piperazin-1-ylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1CCNCC1 ZYLZQIMSYNAILC-UHFFFAOYSA-N 0.000 description 2
- ANCGMULFSINIJZ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1CCNCC1=CN=C(C#N)N=C1NCC(C)(C)C ANCGMULFSINIJZ-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- OMYQJAFUTDFJLN-UHFFFAOYSA-N methyl 4-[4-(2-methoxyethyl)piperazin-1-yl]benzoate Chemical compound C1CN(CCOC)CCN1C1=CC=C(C(=O)OC)C=C1 OMYQJAFUTDFJLN-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical class C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BMEMBBFDTYHTLH-UHFFFAOYSA-N 1-(2-methoxyethyl)piperazine Chemical compound COCCN1CCNCC1 BMEMBBFDTYHTLH-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IVIHUCXXDVVSBH-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)N=C1Cl IVIHUCXXDVVSBH-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- CSZRJZRSXHEHRY-UHFFFAOYSA-N 2-cyano-4-(2,2-dimethylpropylamino)-n-[(4-methoxyphenyl)methyl]pyrimidine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CN=C(C#N)N=C1NCC(C)(C)C CSZRJZRSXHEHRY-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- APCAPSIMHWUYIJ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[(2-phenylpropan-2-ylamino)methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(C)(C)C1=CC=CC=C1 APCAPSIMHWUYIJ-UHFFFAOYSA-N 0.000 description 1
- JOHXTYYQNXSMDY-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[(2-pyrrol-1-ylethylamino)methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNCCN1C=CC=C1 JOHXTYYQNXSMDY-UHFFFAOYSA-N 0.000 description 1
- JXRGWEGBKIOKQA-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[(3-piperidin-1-ylpropylamino)methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNCCCN1CCCCC1 JXRGWEGBKIOKQA-UHFFFAOYSA-N 0.000 description 1
- HPEXOTLUKWMGGS-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCC(N2CCCC2)CC1 HPEXOTLUKWMGGS-UHFFFAOYSA-N 0.000 description 1
- YIFUYUVJLMKBDK-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[(3-methoxyphenyl)methylamino]methyl]pyrimidine-2-carbonitrile Chemical compound COC1=CC=CC(CNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 YIFUYUVJLMKBDK-UHFFFAOYSA-N 0.000 description 1
- HUXZJSWFVMGIHO-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[(4-methoxyphenyl)methylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1CNCC1=CN=C(C#N)N=C1NCC(C)(C)C HUXZJSWFVMGIHO-UHFFFAOYSA-N 0.000 description 1
- MNRBVNKPJISHDU-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-(1-phenylcyclopropyl)propan-2-ylamino]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(C)(C)C1(C=2C=CC=CC=2)CC1 MNRBVNKPJISHDU-UHFFFAOYSA-N 0.000 description 1
- RUTASIJMIUTKKF-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-(3-methoxyphenyl)ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound COC1=CC=CC(CCNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 RUTASIJMIUTKKF-UHFFFAOYSA-N 0.000 description 1
- LRKOITQWZCRQCM-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-(4-methoxyphenyl)ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1CCNCC1=CN=C(C#N)N=C1NCC(C)(C)C LRKOITQWZCRQCM-UHFFFAOYSA-N 0.000 description 1
- BHQCPXVWWNCOTG-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-[3-(4-methylpiperazin-1-yl)phenyl]ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCN1C1=CC=CC(CCNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 BHQCPXVWWNCOTG-UHFFFAOYSA-N 0.000 description 1
- VSIICSXFIRGQBJ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-[4-(4-methylpiperazin-1-yl)phenyl]ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1CCNCC1=CN=C(C#N)N=C1NCC(C)(C)C VSIICSXFIRGQBJ-UHFFFAOYSA-N 0.000 description 1
- ZYXRMYUNHIZXEN-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[2-[4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]ethylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOC)CCN1C(C=C1)=CC=C1CCNCC1=CN=C(C#N)N=C1NCC(C)(C)C ZYXRMYUNHIZXEN-UHFFFAOYSA-N 0.000 description 1
- RUXCXIVIJXHUQA-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCC1N1CCN(CC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)CC1 RUXCXIVIJXHUQA-UHFFFAOYSA-N 0.000 description 1
- DVYSVNKOUTVOQQ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOC)CCN1CC1=CN=C(C#N)N=C1NCC(C)(C)C DVYSVNKOUTVOQQ-UHFFFAOYSA-N 0.000 description 1
- OGNFVUATLYMULP-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(2-piperidin-1-ylethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCN(CCN2CCCCC2)CC1 OGNFVUATLYMULP-UHFFFAOYSA-N 0.000 description 1
- MQILQXGBVOIFJF-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(2-pyridin-2-ylethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCN(CCC=2N=CC=CC=2)CC1 MQILQXGBVOIFJF-UHFFFAOYSA-N 0.000 description 1
- UIBGZBVWBIRFBR-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(2-pyridin-4-ylethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCN(CCC=2C=CN=CC=2)CC1 UIBGZBVWBIRFBR-UHFFFAOYSA-N 0.000 description 1
- AWWWVRFWGNYFEC-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCN(CCN2CCCC2)CC1 AWWWVRFWGNYFEC-UHFFFAOYSA-N 0.000 description 1
- ULQZACJMYBYMPV-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound COC1=CC=CC(N2CCN(CC=3C(=NC(=NC=3)C#N)NCC(C)(C)C)CC2)=C1 ULQZACJMYBYMPV-UHFFFAOYSA-N 0.000 description 1
- YNWFEMKQFOQWON-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)CC1 YNWFEMKQFOQWON-UHFFFAOYSA-N 0.000 description 1
- XTSNGYNJQDYWPA-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CN1CCN(CC=2C=CN=CC=2)CC1 XTSNGYNJQDYWPA-UHFFFAOYSA-N 0.000 description 1
- NXGFRWWFFWDLCJ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(C)(C)CC1=CC=C(F)C=C1 NXGFRWWFFWDLCJ-UHFFFAOYSA-N 0.000 description 1
- YMGHSRDYAVLORL-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NCC1=CN=C(C#N)N=C1NCC(C)(C)C YMGHSRDYAVLORL-UHFFFAOYSA-N 0.000 description 1
- KBHYIQJMMLHPEK-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[1-[3-(4-ethylpiperazin-1-yl)phenyl]-2-methylpropan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CC)CCN1C1=CC=CC(CC(C)(C)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 KBHYIQJMMLHPEK-UHFFFAOYSA-N 0.000 description 1
- IYFPNVBSNJKTCA-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[1-[3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2-methylpropan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOC)CCN1C1=CC=CC(CC(C)(C)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 IYFPNVBSNJKTCA-UHFFFAOYSA-N 0.000 description 1
- HKOJVHIXZVWIOH-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[1-[4-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2-methylpropan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOC)CCN1C(C=C1)=CC=C1CC(C)(C)NCC1=CN=C(C#N)N=C1NCC(C)(C)C HKOJVHIXZVWIOH-UHFFFAOYSA-N 0.000 description 1
- UDDAMZBXZWCWLH-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-(4-methoxyphenyl)-2-methylpropyl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1C(C)(C)CNCC1=CN=C(C#N)N=C1NCC(C)(C)C UDDAMZBXZWCWLH-UHFFFAOYSA-N 0.000 description 1
- NFDOOCYYFNPZQI-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-[4-[4-(2-ethoxyethyl)piperazin-1-yl]phenyl]-2-methylpropyl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOCC)CCN1C1=CC=C(C(C)(C)CNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)C=C1 NFDOOCYYFNPZQI-UHFFFAOYSA-N 0.000 description 1
- LCKIHDFYODAFMO-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-1-(3-pyrrolidin-1-ylphenyl)propan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(C)(C)CC1=CC=CC(N2CCCC2)=C1 LCKIHDFYODAFMO-UHFFFAOYSA-N 0.000 description 1
- RDNGSSONZFUEAT-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-1-[3-(4-propan-2-ylpiperazin-1-yl)phenyl]propan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C(C)C)CCN1C1=CC=CC(CC(C)(C)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 RDNGSSONZFUEAT-UHFFFAOYSA-N 0.000 description 1
- PRDXRHPKRKCORC-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-1-[4-(4-methylpiperazin-1-yl)phenyl]propan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1CC(C)(C)NCC1=CN=C(C#N)N=C1NCC(C)(C)C PRDXRHPKRKCORC-UHFFFAOYSA-N 0.000 description 1
- TUOBDFWXRYVRPH-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-1-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]propan-2-yl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1CC(C)(C)NCC1=CN=C(C#N)N=C1NCC(C)(C)C TUOBDFWXRYVRPH-UHFFFAOYSA-N 0.000 description 1
- KJCRYRTUMPROGJ-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-2-[4-(4-methylpiperazin-1-yl)phenyl]propyl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCN1C1=CC=C(C(C)(C)CNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)C=C1 KJCRYRTUMPROGJ-UHFFFAOYSA-N 0.000 description 1
- GSQFCJKGMCQSCE-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[2-methyl-2-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]propyl]amino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C(C)C)CCN1C1=CC=C(C(C)(C)CNCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)C=C1 GSQFCJKGMCQSCE-UHFFFAOYSA-N 0.000 description 1
- YXCILDBYKFKDPY-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[4-(4-methylpiperazin-1-yl)phenyl]methylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1CNCC1=CN=C(C#N)N=C1NCC(C)(C)C YXCILDBYKFKDPY-UHFFFAOYSA-N 0.000 description 1
- UWPHOJFPDMAZLV-UHFFFAOYSA-N 4-(2,2-dimethylpropylamino)-5-[[[4-[4-(2-ethoxyethyl)piperazin-1-yl]phenyl]methylamino]methyl]pyrimidine-2-carbonitrile Chemical compound C1CN(CCOCC)CCN1C(C=C1)=CC=C1CNCC1=CN=C(C#N)N=C1NCC(C)(C)C UWPHOJFPDMAZLV-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- KSWGPGWIHUIGJM-UHFFFAOYSA-N 5-(aminomethyl)pyrimidine-2-carbonitrile Chemical class NCC1=CN=C(C#N)N=C1 KSWGPGWIHUIGJM-UHFFFAOYSA-N 0.000 description 1
- UNYBOISLSKDKCR-UHFFFAOYSA-N 5-[[4-[2-(diethylamino)ethyl]piperazin-1-yl]methyl]-4-(2,2-dimethylpropylamino)pyrimidine-2-carbonitrile Chemical compound C1CN(CCN(CC)CC)CCN1CC1=CN=C(C#N)N=C1NCC(C)(C)C UNYBOISLSKDKCR-UHFFFAOYSA-N 0.000 description 1
- JRYNKPJGJBLNSY-UHFFFAOYSA-N 5-[[4-[3-(diethylamino)propyl]piperazin-1-yl]methyl]-4-(2,2-dimethylpropylamino)pyrimidine-2-carbonitrile Chemical compound C1CN(CCCN(CC)CC)CCN1CC1=CN=C(C#N)N=C1NCC(C)(C)C JRYNKPJGJBLNSY-UHFFFAOYSA-N 0.000 description 1
- CDMYCQLYQYWGIK-UHFFFAOYSA-N 5-bromo-2-chloro-n-(2,2-dimethylpropyl)pyrimidin-4-amine Chemical compound CC(C)(C)CNC1=NC(Cl)=NC=C1Br CDMYCQLYQYWGIK-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- FMKMKBLHMONXJM-UHFFFAOYSA-N 5-methyl-2-phenylpyrazol-3-amine Chemical compound N1=C(C)C=C(N)N1C1=CC=CC=C1 FMKMKBLHMONXJM-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- WWLSIDZWDPLGIE-UHFFFAOYSA-N CC(C)(C)CNC1=NC(C#N)=NC=C1C(O)=O.COC1=CC=C(CN)C=C1 Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1C(O)=O.COC1=CC=C(CN)C=C1 WWLSIDZWDPLGIE-UHFFFAOYSA-N 0.000 description 1
- XWXGRCUZGMGJTK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1ccc(C)cc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1ccc(C)cc1)=O XWXGRCUZGMGJTK-UHFFFAOYSA-N 0.000 description 1
- IHNJBUJNCPDVGE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc(C)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc(C)c1)=O IHNJBUJNCPDVGE-UHFFFAOYSA-N 0.000 description 1
- HNPZNYXISVHMGT-DDPXNHEPSA-N CCC(CCC(C)C)C[C@](C)(C([C@@H](C)C(C)C)=C)NC Chemical compound CCC(CCC(C)C)C[C@](C)(C([C@@H](C)C(C)C)=C)NC HNPZNYXISVHMGT-DDPXNHEPSA-N 0.000 description 1
- XIQFBPIJSFBPHL-UHFFFAOYSA-N CCCc(cc1)ccc1N1CCN(CCOCC)CC1 Chemical compound CCCc(cc1)ccc1N1CCN(CCOCC)CC1 XIQFBPIJSFBPHL-UHFFFAOYSA-N 0.000 description 1
- HGZDSURFGRAURM-UHFFFAOYSA-N CCOCCN(CC1)CCN1c1cccc(C)c1 Chemical compound CCOCCN(CC1)CCN1c1cccc(C)c1 HGZDSURFGRAURM-UHFFFAOYSA-N 0.000 description 1
- LHROKLSNUJKPQF-UHFFFAOYSA-N CNc1ccn[n]1-c1ccccc1 Chemical compound CNc1ccn[n]1-c1ccccc1 LHROKLSNUJKPQF-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- RHMKHHKLUQJETI-UHFFFAOYSA-N Cc(cc1NC)n[n]1-c1ccccc1 Chemical compound Cc(cc1NC)n[n]1-c1ccccc1 RHMKHHKLUQJETI-UHFFFAOYSA-N 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101100458287 Saguinus oedipus MSPE gene Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical class O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- RIUMNCBSDLWUIX-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-3-[2-(dimethylamino)ethoxy]-4-methoxybenzamide Chemical compound C1=C(OCCN(C)C)C(OC)=CC=C1C(=O)NCC1=CN=C(C#N)N=C1NCC(C)(C)C RIUMNCBSDLWUIX-UHFFFAOYSA-N 0.000 description 1
- HQOIDCLDRARNIX-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-3-[3-(4-ethylpiperazin-1-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(CC)CCN1C1=CC=CC(CC(C)(C)C(=O)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 HQOIDCLDRARNIX-UHFFFAOYSA-N 0.000 description 1
- QBTANFWYJLWRSN-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-3-[3-[4-(2-ethoxyethyl)piperazin-1-yl]phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(CCOCC)CCN1C1=CC=CC(CC(C)(C)C(=O)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 QBTANFWYJLWRSN-UHFFFAOYSA-N 0.000 description 1
- OFCCAZOJEKAQFO-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-3-[3-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(CCOC)CCN1C1=CC=CC(CC(C)(C)C(=O)NCC=2C(=NC(=NC=2)C#N)NCC(C)(C)C)=C1 OFCCAZOJEKAQFO-UHFFFAOYSA-N 0.000 description 1
- VOOUHCIDGIMESB-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-3-[4-(4-ethylpiperazin-1-yl)phenyl]-2,2-dimethylpropanamide Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1CC(C)(C)C(=O)NCC1=CN=C(C#N)N=C1NCC(C)(C)C VOOUHCIDGIMESB-UHFFFAOYSA-N 0.000 description 1
- NTNVVSJWYQTRMA-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-4-[(dimethylamino)methyl]benzamide Chemical compound C1=CC(CN(C)C)=CC=C1C(=O)NCC1=CN=C(C#N)N=C1NCC(C)(C)C NTNVVSJWYQTRMA-UHFFFAOYSA-N 0.000 description 1
- KNRHHZPUOYXYNA-UHFFFAOYSA-N n-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-4-piperazin-1-ylbenzamide Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(=O)C1=CC=C(N2CCNCC2)C=C1 KNRHHZPUOYXYNA-UHFFFAOYSA-N 0.000 description 1
- ORIIDIMWEBEWJV-UHFFFAOYSA-N n-[[2-cyano-4-(2-methylpropylamino)pyrimidin-5-yl]methyl]-4-piperazin-1-ylbenzamide Chemical compound CC(C)CNC1=NC(C#N)=NC=C1CNC(=O)C1=CC=C(N2CCNCC2)C=C1 ORIIDIMWEBEWJV-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- OMTAJYQMQGQCSG-UHFFFAOYSA-N tert-butyl 4-[3-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methylcarbamoyl]phenyl]piperazine-1-carboxylate Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(=O)C1=CC=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 OMTAJYQMQGQCSG-UHFFFAOYSA-N 0.000 description 1
- BPVSNMGOPZXORW-UHFFFAOYSA-N tert-butyl 4-[4-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methylcarbamoyl]phenyl]piperazine-1-carboxylate Chemical compound CC(C)(C)CNC1=NC(C#N)=NC=C1CNC(=O)C1=CC=C(N2CCN(CC2)C(=O)OC(C)(C)C)C=C1 BPVSNMGOPZXORW-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0121026.9 | 2001-08-30 | ||
| GB0121024A GB0121024D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
| GBGB0121026.9A GB0121026D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
| GB0121024.4 | 2001-08-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004109812A RU2004109812A (ru) | 2005-10-20 |
| RU2326119C2 true RU2326119C2 (ru) | 2008-06-10 |
Family
ID=26246490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004109812/04A RU2326119C2 (ru) | 2001-08-30 | 2002-08-29 | 2-циано-4-аминопиримидиновые соединения с ингибирующим действием на катепсин к, фармацевтическая композиция и способы их получения (варианты) |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7112589B2 (enExample) |
| EP (1) | EP1423121B1 (enExample) |
| JP (1) | JP4131701B2 (enExample) |
| KR (1) | KR100629834B1 (enExample) |
| CN (1) | CN1549717B (enExample) |
| AR (1) | AR036375A1 (enExample) |
| AT (1) | ATE345136T1 (enExample) |
| AU (1) | AU2002333758B2 (enExample) |
| BR (1) | BR0212141A (enExample) |
| CA (1) | CA2456127C (enExample) |
| CO (1) | CO5560576A2 (enExample) |
| DE (1) | DE60216122T2 (enExample) |
| ES (1) | ES2275946T3 (enExample) |
| HU (1) | HUP0401431A3 (enExample) |
| IL (1) | IL160295A0 (enExample) |
| MX (1) | MXPA04001930A (enExample) |
| NZ (1) | NZ531287A (enExample) |
| PE (1) | PE20030772A1 (enExample) |
| PL (1) | PL208280B1 (enExample) |
| PT (1) | PT1423121E (enExample) |
| RU (1) | RU2326119C2 (enExample) |
| WO (1) | WO2003020278A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2548684C2 (ru) * | 2010-11-05 | 2015-04-20 | Ф. Хоффманн-Ля Рош Аг | Производные пирролидина для применения в качестве ингибиторов катепсина |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| WO2005014006A1 (en) * | 2003-07-21 | 2005-02-17 | Novartis Ag | Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| WO2005011703A1 (en) * | 2003-08-04 | 2005-02-10 | Akzo Nobel N.V. | 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| WO2005049028A1 (en) * | 2003-11-19 | 2005-06-02 | Novartis Ag | Use of cathepsin k inhibitors in severe bone loss diseases |
| US20070232586A1 (en) * | 2004-04-21 | 2007-10-04 | Kazuyuki Ohmoto | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof |
| TW200614993A (en) * | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| WO2006027211A1 (en) * | 2004-09-07 | 2006-03-16 | Glaxo Group Limited | 2,4-substituted pyrimidines as cysteine protease inhibitors |
| WO2006040300A1 (en) * | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
| IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
| GB0514684D0 (en) * | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| CA2617725C (en) * | 2005-08-05 | 2012-04-03 | Hybrigenics Sa | Novel cysteine protease inhibitors and their therapeutic applications |
| WO2007025776A2 (en) * | 2005-09-02 | 2007-03-08 | Glaxo Group Limited | Cysteine protease inhibitors |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| CA2652600A1 (en) * | 2006-05-22 | 2007-11-29 | Velcura Therapeutics, Inc. | Use of cathepsin k antagonists in bone production |
| US20090227579A1 (en) * | 2006-06-23 | 2009-09-10 | Astrazeneca Ab | Pteridine Derivatives and their Use as Cathespin Inhibitors |
| EP1947091A1 (en) * | 2007-01-16 | 2008-07-23 | Glaxo Group Limited | Pyrimidyl nitrile derivatives as cysteine protease inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2489656A1 (en) | 2007-12-21 | 2012-08-22 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| US9115126B2 (en) | 2010-01-15 | 2015-08-25 | Merck Sharp & Dohme B.V. | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| WO2018138356A1 (en) * | 2017-01-27 | 2018-08-02 | Genfit | Rorgamma modulators and uses thereof |
| CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN109467536B (zh) * | 2018-12-23 | 2020-06-05 | 沧州普瑞东方科技有限公司 | 2-氯/羟基嘧啶-5-羧酸的合成方法 |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019816A1 (en) * | 1999-09-13 | 2001-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270922A (enExample) | 1960-11-02 | |||
| NL295648A (enExample) * | 1962-07-26 | |||
| BR6915234D0 (pt) | 1969-05-22 | 1973-06-07 | American Cyanamid Co | Novos derivados de melamina e processo para sua preparaca |
| CH627919A5 (de) * | 1977-04-14 | 1982-02-15 | Ciba Geigy Ag | Herbizide mittel. |
| WO1997009315A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| AU1608397A (en) | 1996-02-02 | 1997-08-22 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| DE19817459A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue heterozyklische substituierte Amide, Herstellung und Anwendung |
| IL148291A0 (en) * | 1999-09-16 | 2002-09-12 | Tanabe Seiyaku Co | Aromatic nitrogen-containing 6-membered cyclic compounds |
| CN1440393A (zh) * | 2000-04-28 | 2003-09-03 | 田边制药株式会社 | 环状化合物 |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
-
2002
- 2002-08-28 AR ARP020103230A patent/AR036375A1/es not_active Application Discontinuation
- 2002-08-29 PL PL367821A patent/PL208280B1/pl not_active IP Right Cessation
- 2002-08-29 US US10/487,741 patent/US7112589B2/en not_active Expired - Fee Related
- 2002-08-29 BR BR0212141-7A patent/BR0212141A/pt not_active IP Right Cessation
- 2002-08-29 AU AU2002333758A patent/AU2002333758B2/en not_active Ceased
- 2002-08-29 EP EP02797650A patent/EP1423121B1/en not_active Expired - Lifetime
- 2002-08-29 ES ES02797650T patent/ES2275946T3/es not_active Expired - Lifetime
- 2002-08-29 KR KR1020047002973A patent/KR100629834B1/ko not_active Expired - Fee Related
- 2002-08-29 IL IL16029502A patent/IL160295A0/xx unknown
- 2002-08-29 PE PE2002000834A patent/PE20030772A1/es not_active Application Discontinuation
- 2002-08-29 HU HU0401431A patent/HUP0401431A3/hu unknown
- 2002-08-29 CN CN028169638A patent/CN1549717B/zh not_active Expired - Fee Related
- 2002-08-29 RU RU2004109812/04A patent/RU2326119C2/ru not_active IP Right Cessation
- 2002-08-29 AT AT02797650T patent/ATE345136T1/de active
- 2002-08-29 MX MXPA04001930A patent/MXPA04001930A/es active IP Right Grant
- 2002-08-29 DE DE60216122T patent/DE60216122T2/de not_active Expired - Lifetime
- 2002-08-29 CA CA002456127A patent/CA2456127C/en not_active Expired - Fee Related
- 2002-08-29 NZ NZ531287A patent/NZ531287A/en unknown
- 2002-08-29 JP JP2003524585A patent/JP4131701B2/ja not_active Expired - Fee Related
- 2002-08-29 PT PT02797650T patent/PT1423121E/pt unknown
- 2002-08-29 WO PCT/EP2002/009661 patent/WO2003020278A1/en not_active Ceased
-
2004
- 2004-02-25 CO CO04016657A patent/CO5560576A2/es not_active Application Discontinuation
-
2005
- 2005-11-30 US US11/291,007 patent/US20060074092A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019816A1 (en) * | 1999-09-13 | 2001-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2548684C2 (ru) * | 2010-11-05 | 2015-04-20 | Ф. Хоффманн-Ля Рош Аг | Производные пирролидина для применения в качестве ингибиторов катепсина |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04001930A (es) | 2004-06-15 |
| DE60216122T2 (de) | 2007-09-06 |
| ES2275946T3 (es) | 2007-06-16 |
| KR20040029101A (ko) | 2004-04-03 |
| CO5560576A2 (es) | 2005-09-30 |
| CN1549717B (zh) | 2011-08-17 |
| CA2456127C (en) | 2009-10-20 |
| JP2005505550A (ja) | 2005-02-24 |
| WO2003020278A1 (en) | 2003-03-13 |
| DE60216122D1 (de) | 2006-12-28 |
| AR036375A1 (es) | 2004-09-01 |
| PL208280B1 (pl) | 2011-04-29 |
| PT1423121E (pt) | 2007-02-28 |
| BR0212141A (pt) | 2004-08-24 |
| KR100629834B1 (ko) | 2006-09-29 |
| US7112589B2 (en) | 2006-09-26 |
| NZ531287A (en) | 2005-12-23 |
| US20060074092A1 (en) | 2006-04-06 |
| AU2002333758B2 (en) | 2006-01-19 |
| PE20030772A1 (es) | 2003-10-02 |
| ATE345136T1 (de) | 2006-12-15 |
| HUP0401431A2 (hu) | 2004-10-28 |
| IL160295A0 (en) | 2004-07-25 |
| PL367821A1 (en) | 2005-03-07 |
| CA2456127A1 (en) | 2003-03-13 |
| EP1423121A1 (en) | 2004-06-02 |
| RU2004109812A (ru) | 2005-10-20 |
| JP4131701B2 (ja) | 2008-08-13 |
| US20040249153A1 (en) | 2004-12-09 |
| HUP0401431A3 (en) | 2004-11-29 |
| EP1423121B1 (en) | 2006-11-15 |
| CN1549717A (zh) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2326119C2 (ru) | 2-циано-4-аминопиримидиновые соединения с ингибирующим действием на катепсин к, фармацевтическая композиция и способы их получения (варианты) | |
| CN104125957B (zh) | 取代的苄基吡唑 | |
| TWI715593B (zh) | 新穎羥基酸衍生物，其製備方法及含彼等之醫藥組合物 | |
| JP4629334B2 (ja) | システインプロテアーゼの阻害因子としてのピロロピリミジン | |
| CN103097340B (zh) | 治疗活性组合物及其使用方法 | |
| KR102710425B1 (ko) | 항증식 활성을 갖는 피페리디노벤조디아제핀 화합물 | |
| AU2002333758A1 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | |
| JP2015511217A (ja) | 治療活性化合物およびそれらの使用方法 | |
| CN106211770B (zh) | 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 | |
| EP3523292B1 (en) | Heteroaryl compounds and their use as mer inhibitors | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| JP2023552632A (ja) | アンドロゲン受容体及びホスホジエステラーゼ二重阻害剤としての新規化合物 | |
| CN110872277B (zh) | N-取代芳环-2-氨基嘧啶类化合物及用途 | |
| JP7390487B2 (ja) | 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体 | |
| CN107531680B (zh) | 一种毒素及其中间体的制备方法 | |
| CN105658644B (zh) | 取代咪唑用作n型钙通道阻滞剂 | |
| CN120813573A (zh) | 用于治疗癌症的化合物和方法 | |
| TWI768781B (zh) | 轉化生長因子－β受體抑制劑 | |
| WO2004101567A1 (en) | 2-SUBSTITUTED PHENYL -6,8-DIALKYL-3H-IMIDAZOLE [1,5a][1,3,5] TRIAZINE -4- ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | |
| HK40012561B (en) | Heteroaryl compounds and their use as mer inhibitors | |
| EA040562B1 (ru) | Соединения пиперидинобензодиазепина, обладающие антипролиферативной активностью | |
| HK1250923A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| FR3061177A1 (fr) | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| JPWO2001027105A1 (ja) | ピリミジン−５−カルボキサミド化合物、その製造法および用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140830 |